Abstract
Management of men with prostate cancer is fraught with uncertainty as physicians and patients balance efficacy with potential toxicity and diminished quality of life. Utilization of genomics as a prognostic biomarker has improved the informed decision-making process by enabling more rationale treatment choices. Recently investigations have begun to determine whether genomic information from tumor transcriptome data can be used to impact clinical decision-making beyond prognosis. Here we discuss the potential of genomics to alter management of a patient who presented with high-risk prostate adenocarcinoma. We suggest that this information help selecting patients for advanced imaging, chemotherapies, or clinical trial.
Original language | English (US) |
---|---|
Pages (from-to) | 51-54 |
Number of pages | 4 |
Journal | Urology Case Reports |
Volume | 9 |
DOIs | |
State | Published - Nov 1 2016 |
Keywords
- Genomics
- Neuroendocrine
- Prostate
ASJC Scopus subject areas
- Urology